PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment

• Status: NOT_YET_RECRUITING
• Trial end date: 2030-12-01

Summary

The main objective of PANORAMIX phase II trial is to optimize first-lie (L1) NALIRIFOX treatment for pancreatic cancer through the implementation of 5-fluorouracil (5-FU) maintenance therapy. Additionally, it aims to investigate the role of antibiotics and microbiota in second-line (L2) treatment.

• Phase: PHASE2

Details

• Lead Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group
• Collaborator: Servier
• Treatments: Ciprofloxacin; Fluorouracil; Gemcitabine; irinotecan sucrosofate; Leucovorin; Oxaliplatin; Paclitaxel